Idex Corp. price target raised to $248 from $236 at RBC Capital

RBC Capital analyst Deane Dray raised the firm’s price target on Idex Corp. (IEX) to $248 from $236 and keeps an Outperform rating on the shares after its Q3 earnings beat. The company reported a modest 1% operating income beat and boosted the low-end of 2024 guidance, though the most significant positive driving the 7% relief rally was commentary about stabilization in the life sciences part of Health & Science Technologies segment after a protracted period of destocking/malaise, the analyst tells investors in a research note.